Traws Pharma, Inc.
TRAW
Rank in Stocks
#31092
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage,... Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Share Price
$0.24
Last synced: 2026-11-09
Market Cap
$3.69M
Change (1 day)
8.16%
Change (1 year)
-88.79%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Traws Pharma, Inc. (TRAW)
Category
Healthcare
EPS for Traws Pharma, Inc. (TRAW)
EPS as of June 2026 TTM: $-0.50
According to Traws Pharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.50. At the end of 2025 the company had an EPS of $0.83, an increase over its 2024 EPS of $-35.21.
EPS history for Traws Pharma, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.50 | -160.24% |
| 2025 | $0.83 | -102.36% |
| 2024 | $-35.21 | 56.01% |
| 2023 | $-22.57 | -0.47% |
| 2022 | $-22.68 | -5.54% |
| 2021 | $-24.01 | -55.71% |
| 2020 | $-54.21 | -90.33% |
| 2019 | $-560.58 | -70.03% |
| 2018 | $-1.87K | -87.58% |
| 2017 | $-15.06K | -39.72% |
| 2016 | $-24.98K | -57.71% |
| 2015 | $-59.06K | -64.29% |
| 2014 | $-165.38K | -51.96% |
| 2013 | $-344.25K | 129.21% |
| 2012 | $-150.19K | 11.72% |
| 2011 | $-134.44K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,232.00% |
US
|
|
| $-7.07 | 1,314.00% |
US
|
|
| $-5.29 | 958.00% |
AU
|
|
| $12.88 | -2,676.02% |
BE
|
|
| $21.56 | -4,412.00% |
NL
|
Questions about Traws Pharma, Inc.'s earnings per share (EPS)
What is Traws Pharma, Inc.'s earnings per share (EPS)?
Traws Pharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.50, as of Jun 2026.
What was Traws Pharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Traws Pharma, Inc.'s earnings per share (EPS) was $0.83, compared with $-35.21 in 2024.
How has Traws Pharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Traws Pharma, Inc.'s earnings per share (EPS) was highest in 2025 ($0.83) and lowest in 2020 ($-54.21).
How does Traws Pharma, Inc.'s earnings per share (EPS) compare with similar companies?
Traws Pharma, Inc.'s earnings per share (EPS) ($-0.50) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.